For hospital pharmacy directors at orthopedic departments, rheumatology specialists treating osteoarthritis (OA) and bone hyperplasia, and pharmaceutical procurement managers at public healthcare systems, a persistent clinical challenge remains: conventional treatments for degenerative joint diseases include NSAIDs (gastrointestinal and cardiovascular risks), corticosteroids (limited duration of use due to side effects), and opioids (addiction risk). Patients with chronic musculoskeletal pain require safer, non-addictive, disease-modifying options that reduce inflammation and promote tissue repair. Bone melon extract injection directly addresses this need as a botanical-derived therapeutic administered via intravenous or intramuscular injection, designed to reduce inflammation, relieve pain, and promote repair of damaged tissues in musculoskeletal system diseases caused by arthritis and bone hyperplasia. According to the latest industry benchmark, the global market for Bone Melon Extract Injection was valued at USD 10.3 million in 2024 and is forecast to reach a readjusted size of USD 14.5 million by 2031, growing at a modest compound annual growth rate (CAGR) of 3.3% during the forecast period 2025-2031. This niche, slow-growth market reflects concentrated regional demand (primarily China), limited clinical evidence outside Asia, and the absence of major multinational pharmaceutical participants.
*Global Leading Market Research Publisher QYResearch announces the release of its latest report “Bone Melon Extract Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Bone Melon Extract Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.*
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4662298/bone-melon-extract-injection
1. Product Definition: Botanical Injectable for Musculoskeletal Treatment
Bone melon extract injection (also known as muskmelon seed extract injection or Cucumis melo extract injection) is a botanical-derived pharmaceutical product used primarily to treat musculoskeletal system diseases caused by arthritis (osteoarthritis, rheumatoid arthritis), bone hyperplasia (osteophytes, “bone spurs”), and associated chronic pain conditions. The injection is administered by intravenous (IV) or intramuscular (IM) routes, aiming to reduce inflammation, relieve pain, and promote the repair of damaged tissues, including cartilage and bone. The active ingredients are extracted from the seeds or other parts of the bone melon (Cucumis melo, specifically certain varieties cultivated for medicinal purposes). The mechanism of action is thought to involve: (1) anti-inflammatory effects (modulation of cytokine production, particularly IL-1β, TNF-α, and IL-6), (2) antioxidant activity (reducing oxidative stress in joint tissues), (3) promotion of chondrocyte proliferation and extracellular matrix synthesis (cartilage repair), and (4) inhibition of osteoclast activity (reducing bone resorption in hyperplastic lesions).
This product is primarily used in China and other Asian markets where traditional medicine and botanical injectables are more widely accepted. It is not approved by the US FDA (no NDA) nor by the European Medicines Agency (EMA). Within China, bone melon extract injection is classified as a traditional Chinese medicine (TCM) injection (Chinese Herbal Injection), a category that has faced increased regulatory scrutiny due to safety concerns (adverse events, quality control issues) over the past decade.
Two primary dosage strengths (segment by type – QYResearch classification):
- 5ml:25mg – Higher dosage strength, suitable for severe osteoarthritis, advanced bone hyperplasia, or patients requiring higher therapeutic intensity. Administration protocol may involve longer infusion times (IV) or multiple IM injections.
- 2ml:10mg – Lower dosage strength, suitable for mild-to-moderate arthritis, maintenance therapy, or as initial treatment. May be administered intramuscularly for convenience.
End-user segments (segment by application):
- Hospital – Largest segment (~70-75% of revenue). Administered in rheumatology, orthopedics, and rehabilitation departments under physician supervision. Requires prescription, medical insurance coverage (in China, some regions reimburse for approved indications).
- Clinic – Growing segment (~15-20%). Administered in outpatient clinics and community health centers. Lower per-injection facility fee, more convenient for patients.
- Other – Rehabilitation centers, nursing homes, and home healthcare (limited) (~5-10%).
2. Industry Development Trends: Chinese Market Dominance, Regulatory Scrutiny, and Competition from Alternatives
Based on analysis of corporate annual reports (limited, as companies are Chinese private firms), Chinese pharmaceutical regulatory news (NMPA), and industry trends from Q4 2025 to Q2 2026, four dominant trends shape the bone melon extract injection sector:
2.1 Concentrated Chinese Market and Limited Global Presence
The bone melon extract injection market is almost entirely contained within China. The three manufacturers identified (Kaifeng Kangnuo Pharmaceutical, Harbin Shengtai Biopharmaceutical, Harbin Songhe Pharmaceutical) are all Chinese companies. No major multinational pharmaceutical company (Pfizer, Novartis, Roche, Sanofi, etc.) has entered this market. Export volumes are negligible. The market size (USD 10.3 million in 2024) reflects a niche, regionally confined product. Growth is tied to China’s domestic healthcare spending, aging population, and acceptance of TCM injectables.
2.2 Regulatory Scrutiny of Traditional Chinese Medicine Injectables
Chinese herbal injections have faced significant regulatory challenges. The China National Medical Products Administration (NMPA) has revoked approvals for several TCM injections due to adverse event reports (anaphylaxis, liver/kidney toxicity). In 2018-2019, the NMPA revised labels of dozens of TCM injections, adding boxed warnings and restricting use to hospital settings only (no outpatient use). Bone melon extract injection has not been withdrawn, but the regulatory environment remains cautious. Any safety signal (cluster of adverse events) could lead to restrictions, withdrawal, or labeling changes, significantly impacting market size. Manufacturers invest in pharmacovigilance and post-marketing safety studies.
2.3 Competition from Standard Therapies
Bone melon extract injection competes with: (1) NSAIDs (ibuprofen, naproxen, celecoxib) – widely available, low-cost, but gastrointestinal/renal risks, (2) corticosteroid injections (intra-articular) – more potent anti-inflammatory, but limited to 3-4 injections per year, (3) hyaluronic acid injections (viscosupplementation) – widely used for knee osteoarthritis, evidence-based, (4) biological DMARDs (anti-TNF, IL-6 inhibitors) – for rheumatoid arthritis, expensive but effective, (5) oral supplements (glucosamine, chondroitin, MSM) – available over-the-counter, low-risk. Bone melon extract injection’s market share is small compared to these alternatives.
2.4 Aging Population as Demand Driver
China’s population is aging rapidly. By 2030, an estimated 300 million Chinese will be over 60 years old. Osteoarthritis prevalence increases with age (60%+ in over 60s). The number of knee osteoarthritis cases in China is estimated at 100-150 million. This demographic tailwind supports steady demand for osteoarthritis treatments, including bone melon extract injection. However, the product’s modest 3.3% CAGR suggests that other treatments are capturing most of the growth.
Industry Layering Perspective: Hospital vs. Clinic vs. Other
- Hospital – Largest segment, highest regulatory compliance (injections restricted to hospital settings for TCM products). Includes inpatient and outpatient hospital use. Requires physician prescription.
- Clinic – Smaller segment, limited to clinics with qualified physicians and emergency equipment (due to risk of anaphylactic reactions). May be restricted in some provinces.
- Other – Rehabilitation centers, nursing homes. Limited due to injection safety requirements.
3. Market Segmentation and Competitive Landscape
Segment by Dosage Strength (Type):
- 5ml:25mg – Larger share (~55-60% of revenue). Higher dose for severe conditions.
- 2ml:10mg – Moderate share (~40-45% of revenue). Lower dose for mild/moderate conditions or initial therapy.
Segment by End-User (Application):
- Hospital – Largest (~70-75% of revenue)
- Clinic – Growing (~15-20%)
- Other – Small (~5-10%)
Key Market Players (QYResearch-identified):
The market is highly concentrated, with only three manufacturers (all Chinese). No international competition exists.
- Kaifeng Kangnuo Pharmaceutical Co., Ltd. (Henan Province, China) – Likely market leader (not specified in data). Manufacturer of TCM injections and other pharmaceuticals.
- Harbin Shengtai Biopharmaceutical Co., Ltd. (Heilongjiang Province, China) – Second major player.
- Harbin Songhe Pharmaceutical Co., Ltd. (Heilongjiang Province, China) – Third player.
These companies are private, and financial disclosures are not publicly available (no annual reports accessible). They distribute primarily through hospital procurement channels in their respective provinces and nationally. Competition is moderate; each manufacturer holds a share of regional markets.
4. Exclusive Expert Insights and Recent Developments (Q4 2025 – Q2 2026)
Insight #1 – NMPA Post-Marketing Safety Requirements
In June 2025, NMPA issued updated guidelines for TCM injectables, requiring manufacturers to complete post-marketing safety reevaluation by December 2027, including: (1) active adverse event surveillance, (2) risk management plans, (3) restricted use to qualified hospital settings (no community clinic administration), (4) mandatory training for prescribing physicians. Bone melon extract injection manufacturers have initiated these studies. Compliance costs (estimated USD 200,000-500,000 per product) may reduce profit margins but improve safety profile and regulatory acceptance.
Insight #2 – China’s Volume-Based Procurement (VBP) Impact
China’s National Drug Procurement (VBP) program, which significantly reduces prices for selected generic drugs, has not yet included bone melon extract injection (likely due to low volume and patent status? However, TCM injections are typically not included in VBP). However, provincial-level procurement negotiations have occurred. Estimates suggest that procurement prices have declined 10-15% over the past 3 years, compressing margins for manufacturers. Hospital tender prices for bone melon extract injection are approximately USD 3-5 per 5ml:25mg vial (wholesale). Retail prices to patients are higher (including hospital markup).
Insight #3 – No Major Pipeline Developments
No new dosage forms, indications, or combination products for bone melon extract injection have been announced by manufacturers. No clinical trials registered on ClinicalTrials.gov. The market is stagnant in terms of innovation. Growth relies entirely on population aging and increasing osteoarthritis prevalence, not on product differentiation or expanded indications.
Typical User Case (Q1 2026 – Tertiary Hospital Orthopedics Department, Central China):
A tertiary (Grade A) hospital in Hubei Province treats a 65-year-old female patient with moderate knee osteoarthritis (Kellgren-Lawrence grade III) who cannot tolerate NSAIDs (history of gastritis) and had insufficient response to glucosamine. The rheumatologist prescribes bone melon extract injection (5ml:25mg, once daily IV for 14 days, followed by 2ml:10mg IM twice weekly for 4 weeks). The patient reports 40-50% pain reduction (VAS scale from 7/10 to 3-4/10) after the 14-day course, and 60% reduction after the full 6-week course. No adverse events observed. The hospital pharmacy charges the patient USD 120 for the full course (covered by basic medical insurance, patient co-pay USD 24). The patient continues with maintenance therapy (one 2ml injection every 2 weeks). This case is typical: moderate osteoarthritis patients who fail or are intolerant to first-line therapies.
5. Technical Challenges and Future Pathways
Despite niche stability, significant challenges limit the growth and global expansion of bone melon extract injection:
- Lack of high-quality clinical evidence – Most studies on bone melon extract are in Chinese-language journals with limited peer review. No large, randomized, double-blind, placebo-controlled trials published in high-impact international journals (NEJM, The Lancet, Annals of the Rheumatic Diseases). This prevents approval by FDA, EMA, or PMDA, confining the product to the Chinese market.
- Safety concerns for TCM injectables – TCM injections have a history of adverse events, including anaphylaxis (rate estimated 0.1-1 per 10,000 doses). The NMPA requires hospital-only administration with emergency resuscitation equipment available. Any serious adverse event cluster could trigger withdrawal. Manufacturers must maintain robust pharmacovigilance.
- Competition from newer therapies – The osteoarthritis treatment landscape is evolving: (1) anti-NGF antibodies (tanezumab, though FDA advisory committee voted against approval due to adverse events), (2) gene therapy, (3) stem cell injections, (4) intra-articular corticosteroids and hyaluronic acid remain dominant. Bone melon extract injection does not have a clear advantage over these alternatives.
Future Direction: The bone melon extract injection market will continue its slow 3-4% CAGR through 2031, driven almost exclusively by China’s aging population and increasing osteoarthritis prevalence. No breakthrough growth is expected. Key scenarios to monitor: (1) Potential NMPA withdrawal if safety concerns arise (negative market impact), (2) Inclusion in Volume-Based Procurement (price erosion, volume increase uncertain), (3) Expansion to other Asian markets (Vietnam, Indonesia, Thailand) where TCM is accepted (unlikely due to regulatory barriers). For investors, this is a stable but low-growth, region-specific niche. For pharmaceutical companies, there is no incentive to enter unless new clinical evidence emerges. For patients, bone melon extract injection offers a botanical alternative for those who cannot tolerate standard therapies, but evidence-based choices (hyaluronic acid, physical therapy, weight loss) remain preferred.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
